Shares of Cooper Companies COO were flat in after-market trading after the company reported Q4 results.
Quarterly Results
Earnings per share fell 4.24% year over year to $3.16, which beat the estimate of $3.09.
Revenue of $681,600,000 decreased by 1.45% from the same period last year, which beat the estimate of $676,200,000.
Looking Ahead
Cooper Companies Sees Q1 Adj. EPS $2.66-$2.86 vs $2.88 Est., Sales $642M-$670M vs $661.75M Est.
Details Of The Call
Date: Dec 03, 2020
Time: 05:00 PM
ET Webcast URL: https://edge.media-server.com/mmc/p/3t9ku6n3
Price Action
Company's 52-week high was at $371.59
52-week low: $236.68
Price action over last quarter: Up 4.48%
Company Overview
Cooper Companies operates two units: CooperVision and CooperSurgical. Accounting for approximately 75% of total sales, CooperVision is the the second-largest player in the oligopolistic contact lens market. Over 50% of CooperVision's sales are in international territories. The second unit, CooperSurgical, develops and manufactures diagnostic and surgical products for gynecologists and obstetricians, including the Paragard IUD, which Cooper acquired from Teva in 2017.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
